Literature DB >> 10180754

How to calculate indirect costs in economic evaluations.

W B Brouwer, M A Koopmanschap.   

Abstract

Mesh：

Year:  1998        PMID： 10180754     DOI： 10.2165/00019053-199813050-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  7 in total

1.  How to calculate indirect costs in economic evaluations.

Authors:  B Liljas
Journal:  Pharmacoeconomics       Date:  1998-01       Impact factor: 4.981

2.  Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

Authors:  W B Brouwer; M A Koopmanschap; F F Rutten
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

3.  Avoiding double-counting in pharmacoeconomic studies.

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

4.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

5.  Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire.

Authors:  L van Roijen; M L Essink-Bot; M A Koopmanschap; G Bonsel; F F Rutten
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

Review 6.  The consequence of production loss or increased costs of production.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

7.  Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel.

Authors:  W B Brouwer; M A Koopmanschap; F F Rutten
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188
  7 in total
  11 in total

Review 1.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.

Authors:  K Puolakka; H Kautiainen; M Pekurinen; T Möttönen; P Hannonen; M Korpela; M Hakala; M Arkela-Kautiainen; R Luukkainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

Review 4.  [The cost of sepsis].

Authors:  O Moerer; H Burchardi
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

5.  Different approaches to valuing the lost productivity of patients with migraine.

Authors:  J H Lofland; J C Locklear; K D Frick
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Measuring productivity changes in economic evaluation: setting the research agenda.

Authors:  Marc Koopmanschap; Alex Burdorf; Karin Jacob; Willem Jan Meerding; Werner Brouwer; Hans Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  The significance of presenteeism for the value of lost production: the case of rheumatoid arthritis.

Authors:  Rikke Søgaard; Jan Sørensen; Louise Linde; Merete L Hetland
Journal:  Clinicoecon Outcomes Res       Date:  2010-07-16

8.  Protocol of the impact of alternative social assistance disbursement on drug-related harm (TASA) study: a randomized controlled trial to evaluate changes to payment timing and frequency among people who use illicit drugs.

Authors:  Lindsey Richardson; Allison Laing; M-J Milloy; Russ Maynard; Bohdan Nosyk; Brandon Marshall; Eric Grafstein; Patricia Daly; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  BMC Public Health       Date:  2016-07-29       Impact factor: 3.295

9.  Effectiveness and cost-effectiveness of Self-Help Plus (SH+) for preventing mental disorders in refugees and asylum seekers in Europe and Turkey: study protocols for two randomised controlled trials.

Authors:  Marianna Purgato; Kenneth Carswell; Ceren Acarturk; Teresa Au; Sena Akbai; Minna Anttila; Josef Baumgartner; Della Bailey; Massimo Biondi; Martha Bird; Rachel Churchill; Sevde Eskici; Louise Juul Hansen; Paul Heron; Zeynep Ilkkursun; Reinhold Kilian; Markus Koesters; Tella Lantta; Michela Nosè; Giovanni Ostuzzi; Davide Papola; Mariana Popa; Marit Sijbrandij; Lorenzo Tarsitani; Federico Tedeschi; Giulia Turrini; Ersin Uygun; Maritta Anneli Välimäki; Johannes Wancata; Ross White; Elisa Zanini; Pim Cuijpers; Corrado Barbui; Mark Van Ommeren
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

10.  Moving towards an organized cervical cancer screening: costs and impact.

Authors:  Mireia Diaz; David Moriña; Vanesa Rodríguez-Salés; Raquel Ibáñez; Josep Alfons Espinás; Silvia de Sanjosé
Journal:  Eur J Public Health       Date:  2018-12-01       Impact factor: 3.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.